News, Events & Resources | Crystal Bio Solutions

Hybrid LC-MS/MS for Large Molecule and ADC Bioanalysis

Written by Crystal Bio Solutions Scientific Team | Nov 21, 2026, 9:12:02 PM

Hybrid LC-MS/MS, also called immunocapture or immunoaffinity LC-MS/MS, combines an affinity capture step with mass spectrometric detection. It is used to quantify antibodies, bispecifics, ADCs and other protein therapeutics when a ligand-binding assay (LBA) is not practical or not specific enough.

This article explains how the method works, when it is the better choice, its limitations, and how it is validated for regulated studies.

How hybrid LC-MS/MS works

  1. Capture. The drug is enriched from serum or plasma with a capture reagent: the target antigen, an anti-idiotypic antibody, a generic anti-human Fc antibody (common in animal studies), or protein A or G.
  2. Digestion or release. The captured protein is digested, usually with trypsin, to produce signature peptides. For ADCs with an enzyme-cleavable linker, the payload can instead be released enzymatically to measure conjugated payload.
  3. Quantification. A triple quadrupole LC-MS/MS measures the signature peptide or released payload against a stable isotope-labeled internal standard (peptide or, preferably, protein).

Only one binding reagent is needed, compared with two for a typical sandwich LBA, and detection is based on the analyte's mass rather than a second binding event.

When to choose hybrid LC-MS/MS over a ligand-binding assay

SituationWhy hybrid LC-MS/MS helps
No anti-idiotypic reagents yet (early development)Generic capture plus a signature peptide from the human constant region works in animal matrices for many IgG1 and IgG4 molecules
ADC conjugated payloadReleased payload is measured directly; with total antibody it gives the average DAR over time
Bispecifics and multidomain proteinsPeptides from different domains can show whether the molecule stays intact
Specificity concerns (cross-reactivity, soluble target, ADA)Mass-based detection reduces some interferences; capture choice still determines whether free or total drug is measured
Several analytes from one sampleMultiple peptides or payload can be measured after a single capture

A well-designed LBA is often still preferred when very high sensitivity is needed for a monoclonal antibody in human samples and good reagents exist. Many programs use both: LBA for total antibody and LC-MS/MS for payload-related analytes.

Limitations to plan for

  • Surrogate measurement. A signature peptide reports the protein region it comes from, not proof that the whole molecule is intact. Peptide selection should be justified, and catabolism considered.
  • What the capture defines. Target capture measures drug with a free binding site; generic Fc capture measures total drug, including drug bound to soluble target or ADA. The capture must match the question.
  • Peptide stability and modifications. Peptides prone to deamidation or oxidation are avoided, because in vivo or processing changes would bias results.
  • Sensitivity. For many antibody methods, lower limits of quantification are in the range of tens of ng/mL, which may not match the most sensitive LBAs; enrichment and sample volume affect this.

Validation for regulated studies

Hybrid methods used for regulated PK and toxicokinetic data are validated following ICH M10. Because they combine binding and chromatographic steps, validation addresses selectivity, specificity, calibration curve, accuracy and precision, carry-over, matrix effects, dilution linearity, stability, and incurred sample reanalysis during study sample analysis. Critical reagents, including the capture reagent and internal standard, are characterized and tracked by lot.

How Crystal Bio Solutions supports hybrid LC-MS/MS

Hybrid LC-MS/MS methods are developed, validated and run at our GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California on a SCIEX 7500 triple quadrupole system. For complex analytes, such as ADC payloads, catabolites or modified proteins, the high-resolution mass spectrometry team at our Natick, Massachusetts laboratory helps identify species and select signature peptides during method development.

See our generic LC-MS/MS ADC PK case study, PK assays for biologics and ADCs and strategies for ADC bioanalysis.

LBA, hybrid LC-MS/MS, or both? Discuss your molecule with Dr. Meina Liang, our Chief Scientific Officer & Head of Bioanalysis and Biomarkers

One hour at no cost with the leader who supervises our bioanalysis projects, with a CDA in place first.

Request a Consultation

Frequently Asked Questions

What is hybrid LC-MS/MS?

A bioanalytical method that enriches a protein drug with an affinity capture reagent, digests it or releases its payload, and quantifies a signature peptide or the payload by LC-MS/MS.

When is hybrid LC-MS/MS better than a ligand-binding assay?

When specific reagents are not yet available, when higher specificity is needed, for ADC conjugated payload, for multidomain proteins, or when several analytes should be measured from one sample.

Does hybrid LC-MS/MS measure free or total drug?

It depends on the capture reagent. Target or anti-idiotypic capture tends to measure drug with a free binding site; generic Fc or protein A/G capture tends to measure total drug.

Can hybrid LC-MS/MS be used for regulated studies?

Yes. Methods supporting regulated PK and toxicokinetic data are validated following ICH M10 and run under GLP or GCLP as the study requires.

How is DAR followed in vivo?

By measuring conjugated payload (after enzymatic release) and total antibody in the same samples; their molar ratio gives the average DAR over time.